Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;56(3):570-580.
doi: 10.1038/s41409-020-01060-5. Epub 2020 Sep 17.

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy

Affiliations

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy

Ruimin Hong et al. Bone Marrow Transplant. 2021 Mar.

Abstract

An excessive immune response during coronavirus disease (COVID-19) can induce cytokine release syndrome (CRS), which is associated with life-threatening complications and disease progression. This retrospective study evaluated the clinical characteristics of severe CRS (sCRS, grade 3-4) induced by severe COVID-19 (40 patients) or chimeric antigen receptor T-cell (CAR-T) therapy as a comparator (41 patients). Grade 4 CRS was significantly more common in the COVID-19 group (15/40 (35.7%) vs. 5/41 (12.2%), P = 0.008). The CAR-T group had more dramatic increase in cytokines, including IL-2, IL-6, IL-10, and IFN-γ. Interestingly, COVID-19 group had significantly higher levels for TNF-α (31.1 pg/ml (16.1-70.0) vs. 3.3 (1.8-9.6), P < 0.001) and lg viral loads were correlated with lg IL-6 (R2 = 0.101; P < 0.001) and lg IL-10 (R2 = 0.105; P < 0.001). The independent risk factor for COVID-19-related sCRS was hypertension history (OR: 4.876, 95% CI: 2.038-11.668; P < 0.001). Our study demonstrated that there were similar processes but different intensity of inflammatory responses of sCRS in COVID-19 and CAR-T group. The diagnose and management of severe COVID-19-related sCRS can learn lessons from treatment of sCRS induced by CAR-T therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. Clinical symptoms in patients with grade 3–4 CRS in COVID-19 group (n = 40) and CAR-T group (n = 41).
Data were described as n(%) and median (IQR). Chi-square test and Mann–Whitney U test were used for statistical analysis. Y: yes (had related symptom); N: no (had no related symptom).
Fig. 2
Fig. 2. Peak serum level of cytokine, procalcitonin (PCT), C-reactive protein (CRP), D-dimer (DDI), and ferritin in patients with grade 3–4 CRS in COVID-19 group (n = 40) and CAR-T group (n = 41).
Data were described as median (IQR). The Mann–Whitney U test was used for statistical analysis.
Fig. 3
Fig. 3. Imaging features of the lungs in the COVID-19 and CAR-T groups.
a Transverse chest CT images from a 74-year-old man with grade 4 CRS in COVID-19 group showing bilateral diffuse ground-glass opacity, patchy and streak hyperdensities on day 29 after sCRS onset. b Transverse chest CT images from a 23-year-old woman with grade 4 CRS in CAR-T group showing bilateral patchy hyperdensities, with uneven internal density and pleural effusion on day 8 after sCRS onset.
Fig. 4
Fig. 4. Correlation between viral load/tumor burden and cytokine levels with grade 3–4 CRS in COVID-19 group (n = 40) and CAR-T group (n = 41).
Pearson correlation and linear regression were used for statistical analysis. LDH lactate dehydrogenase.

References

    1. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473–4. doi: 10.1126/science.abb8925. - DOI - PubMed
    1. Oldstone MB, Rosen H. Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule. Curr Top Microbiol Immunol. 2014;378:129–47. - PMC - PubMed
    1. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95.. doi: 10.1182/blood-2014-05-552729. - DOI - PMC - PubMed
    1. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130:2202–5. doi: 10.1172/JCI137647. - DOI - PMC - PubMed
    1. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56. doi: 10.1186/s40425-018-0343-9. - DOI - PMC - PubMed

Publication types

MeSH terms